Analyst Scoreboard: 4 Ratings For IQVIA Hldgs


IQVIA Hldgs IQV underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 1 1 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 1 1 1 0 0
3M Ago 0 0 0 0 0

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $264.25, with a high estimate of $292.00 and a low estimate of $245.00. Observing a downward trend, the current average is 4.02% lower than the prior average price target of $275.33.

Understanding Analyst Ratings: A Comprehensive Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive IQVIA Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Matthew Sykes Goldman Sachs Announces Buy $270.00 -
Elizabeth Anderson Evercore ISI Group Lowers Outperform $250.00 $275.00
Jailendra Singh Truist Securities Lowers Buy $292.00 $297.00
Eric Coldwell Baird Lowers Neutral $245.00 $254.00

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IQVIA Hldgs. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of IQVIA Hldgs compared to the broader market.
  • Price Targets: Gaining insights, analysts provide estimates for the future value of IQVIA Hldgs's stock. This comparison reveals trends in analysts' expectations over time.

To gain a panoramic view of IQVIA Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on IQVIA Hldgs analyst ratings.

All You Need to Know About IQVIA Hldgs

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Hldgs: A Financial Overview

Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.

Revenue Growth: IQVIA Hldgs displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 2.33%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: IQVIA Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.71% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): IQVIA Hldgs's ROE excels beyond industry benchmarks, reaching 4.62%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): IQVIA Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of 1.08%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: IQVIA Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 2.17. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!